- G1 Therapeutics Inc GTHX has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC).
- Cosela will be administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy. Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study. The initial results of this study are expected in the second half of 2022.
- Patient recruitment in Preserve 3 is now underway. The study will enroll approximately 90 patients.
- Price Action: GTHX shares are up 1.06% at $21.85 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
